Pankaj Bhargava, āshibio CEO
June 20, 2024 08:30 AM EDT
Financing
Startups

Gilead test­ed an an­ti­body many times. A small biotech sal­vages it, with $40M and ‘con­vic­tion’ else­where

Kyle LaHucik

Senior Reporter

Gilead had test­ed a hu­man­ized an­ti­body called an­de­cal­ix­imab, or GS-5745, in close to 1,000 pa­tients be­fore giv­ing up on it a few years ago. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times